Fresenius Medical Care AG (NYSE:FMS) Shares Bought by Cerity Partners LLC

Cerity Partners LLC lifted its position in shares of Fresenius Medical Care AG (NYSE:FMS) by 21.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 32,604 shares of the company’s stock after buying an additional 5,853 shares during the quarter. Cerity Partners LLC’s holdings in Fresenius Medical Care were worth $725,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. MML Investors Services LLC lifted its stake in Fresenius Medical Care by 5.3% in the 3rd quarter. MML Investors Services LLC now owns 15,019 shares of the company’s stock valued at $320,000 after buying an additional 753 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Fresenius Medical Care during the 3rd quarter worth about $38,000. Franklin Resources Inc. grew its holdings in shares of Fresenius Medical Care by 3.3% during the third quarter. Franklin Resources Inc. now owns 74,640 shares of the company’s stock worth $1,490,000 after buying an additional 2,386 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Fresenius Medical Care by 18.2% during the third quarter. JPMorgan Chase & Co. now owns 9,902 shares of the company’s stock valued at $211,000 after buying an additional 1,528 shares during the period. Finally, GAMMA Investing LLC boosted its position in Fresenius Medical Care by 43.3% during the fourth quarter. GAMMA Investing LLC now owns 7,164 shares of the company’s stock worth $162,000 after acquiring an additional 2,166 shares during the last quarter. 8.37% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

FMS has been the topic of several analyst reports. Truist Financial raised their price objective on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Monday, January 6th. StockNews.com upgraded Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th.

Fresenius Medical Care Price Performance

Shares of NYSE FMS opened at $23.65 on Monday. The company has a market capitalization of $13.88 billion, a price-to-earnings ratio of 19.54, a PEG ratio of 0.76 and a beta of 0.93. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. Fresenius Medical Care AG has a 1-year low of $17.93 and a 1-year high of $25.96. The business has a 50-day moving average of $23.94 and a 200-day moving average of $22.90.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.